Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22600622 | 1.00 | PTPRB (0.89) | PTPRBPTPN1 | |
| SCHEMBL684260 | 0.94 | PTPRB (1.00) | PTPRBPTPN1 | |
| SCHEMBL18653037 | 0.94 | PTPRB (1.00) | PTPRBPTPN1 | |
| SCHEMBL3568318 | 0.94 | PTPRB (1.00) | PTPRBPTPN1 | |
| SCHEMBL468252 | 0.91 | PTPRB (1.00) | PTPRBPTPN1 | |
| SCHEMBL19493251 | 0.91 | PTPRB (1.00) | PTPRBPTPN1 | |
| SCHEMBL468250 | 0.91 | PTPRB (1.00) | PTPRBPTPN1 | |
| SCHEMBL468029 | 0.84 | PTPRB (0.78) | PTPRBPTPN1 | |
| SCHEMBL3922886 | 0.84 | PTPRB (0.78) | PTPRBPTPN1 | |
| SCHEMBL679188 | 0.84 | PTPRB (0.78) | PTPRBPTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11253502-B2 | Tie-2 activators targeting the Schlemm's canal | EyePoint Pharmaceuticals, Inc. (US) | 2022-02-22 | — | — | US | disclosed |
| US-20200338048-A1 | TIE-2 ACTIVATORS TARGETING THE SCHLEMM'S CANAL | EyePoint, Inc. | 2020-10-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11253502-B2 | Tie-2 activators targeting the Schlemm's canal | TIE1, TEK, TGFB2 | PTPRB 840/4885PTPN1 3438/4885 |
| US-20200338048-A1 | TIE-2 ACTIVATORS TARGETING THE SCHLEMM'S CANAL | TIE1, TEK, TGFB2 | PTPRB 840/4885PTPN1 3438/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.